GlassScriptPhysician profile
Kiah Purcell
NPI 1760092217
$8,276.34
in general payments reported to CMS, 2019-2025
19 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $549 · 2022: $787 · 2023: $2,575 · 2024: $4,242 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,985 · Food and Beverage: $1,056 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $454 · Travel and Lodging: $347 · Education: $98.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,985.00 |
| Food and Beverage | $1,056.05 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $453.74 |
| Travel and Lodging | $347.24 |
| Education | $98.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Global Services, LLC | $3,395.00 | 2024 | |
| Janssen Biotech, INC. | $2,054.71 | 2021-2025 | Darzalex, Talvey, Tecvayli |
| Janssen Research & Development, LLC | $451.27 | 2023 | |
| Celgene Corporation | $343.99 | 2021-2023 | Pomalyst |
| Astrazeneca Pharmaceuticals LP | $290.70 | 2024 | |
| Genzyme Corporation | $278.69 | 2022-2025 | |
| Abbvie INC. | $271.98 | 2022 | |
| Karyopharm Therapeutics INC. | $202.04 | 2021-2025 | Xpovio |
| Taiho Oncology, INC. | $163.04 | 2024 | |
| Sanofi-Aventis U.S. LLC | $133.63 | 2023-2024 | |
| Glaxosmithkline, LLC. | $125.27 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $122.55 | 2023 | Pomalyst |
| Genentech USA, INC. | $100.07 | 2022-2025 | Venclexta, Gazyva |
| Janssen Scientific Affairs, LLC | $90.00 | 2024 | Talvey |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $52.91 | 2023-2024 | Ninlaro |
| Amgen INC. | $33.43 | 2021 | |
| Dova Pharmaceuticals | $22.64 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiah Purcell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.